Abstract
Anticancer therapy-induced cardiotoxicity still remains a serious problem, strongly affecting both quality of life and overall survival of oncologic patients. The most effective approach for minimizing cardiotoxicity is its early detection and prompt prophylactic treatment initiation. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, measurement of serum cardio-specific biomarkers has emerged, resulting in a cost-effective diagnostic tool for early identification of patients more prone to developing cardiotoxicity, in whom a preventive pharmacological strategy and a closer cardiac monitoring are of crucial importance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
